Drug
discovery

The birth of a new drug is an extremely complex process requiring knowledge in multiple scientific fields, from Life Sciences to physics, from engineering to Artificial Intelligence.

This path requires a decades-long effort, from the discovery of the active ingredient to its feasible use on humans.

Our team of Drug Discovery researchers aims at identifying increasingly effective and selective compounds to either improve existing drugs and develop new ones that can act on diseases that are still without a cure.

Our Drug Discovery pipeline

  • DISCOVERY
  • FEASIBILITY
  • HIT FINDING
  • HIT-TO-LEAD
  • LEAD-TO-CANDIDATE
  • CANDIDATE DRUG

C5AR ANTAGONISTS - (NAM) PAIN

TRPM8 BLOCKERS - PAIN

TRPM8 BLOCKERS - UROLOGY

BKB1R ANTAGONISTS - PAIN

CNR2 ANTAGONISTS - PAIN

GPR120 ANTAGONISTS - DIABETES

The company's research and development laboratories are located within the L'Aquila hub.

The drug discovery and technology formulation laboratories are based within the Federico II University of Naples where 1000 square meters are dedicated to the design of new materials, new vehicles, new methods of administering drugs and the characterization and the analysis of the chemical-physical interactions between the drug and the release system.

Our Drug Discovery platform

Our Drug Discovery platform is based on proprietary technological tools (GPCRbase™, Ligen™ and LigandBase™ and MolecularAssemblies) designed to speed up the three stages in the process:

  • Identification of molecular targets;
  • Identification and validation of candidate molecules (lead candidates);
  • Proof-of-concept testing in selected pre-clinical models.
Centres we collaborate with

Following is a list of the centres we collaborate with based on research agreements and material transfer agreements (MTAs), per therapeutic area:

INFLAMMATORY AND NEUROPATHIC PAIN

Project C5aR

  • Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de SãoPaulo, Brazil
  • Departamento de Bioquímica e Immunologia, Instituto Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
  • Dipartimento di Farmacologia Sperimentale, Università degli Studi di Napoli Federico II, Napoli, Italy

ONCOLOGY

Platform IL-8

  • The Research Institute at Nationwide Children’s Hospital, Columbus, USA
  • Universidad Pública de Navarra, Pamplona, Spain
  • Federico II University, Napoli, Italy
  • Spanish National Centre for Cardiovascular Research, Madrid, Spain
  • The Ohio State University Comprehensive Cancer Center, USA
  • Mount Sinai School of Medicine, New York, USA
  • National Cancer Institute, Washington, USA
  • Virginia Commonwealth University, USA

OPHTALMOLOGY

Project TRPM8

  • ORA, Inc., Andover, MA, USA

Platform IL-8

  • Helsinki University Hospital, Helsinki, Finland

Project rhNGF

  • University College London, London, United Kingdom
  • Bascom Palmer Eye Institute, Miami, USA
  • Università degli studi di Firenze, Firenze, Italy

DIABETES

Project GPR120

  • Dipartimento di Scienze mediche traslazionali, Università degli Studi di Napoli Federico II, Napoli, Italy

Platform IL-8

  • Istituto Scientifico San Raffaele, Milano, Italy

UROLOGY

Project TRPM8

  • Istituto di Ricerca Urologica (URI), Istituto Scientifico San Raffaele, Milano, Italy

Platform IL-8

  • Istituto di Ricerca Urologica (URI), Istituto Scientifico San Raffaele, Milano, Italy

INFLAMMATION

Platform IL-8

  • Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
  • University of Texas Medical Branch. Virginia Commonwealth University, USA

PAIN

Project TRPM8

  • Dipartimento di Farmacologia Sperimentale, Università degli Studi di Napoli Federico II, Napoli, Italy
OUR DRUG DISCOVERY PARTNERS
For our Drug Discovery activities we are currently partnering with the following companies:

Dompé Farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153